Break it Down: Paradigm Biopharmaceuticals en route to Phase 3 clinical trial with FDA support
Stockhead TV’s Sarah Hughan brings you today’s Break it Down, detailing the US Government support for a knee osteoarthritis drug from Paradigm Biopharmaceuticals.
Stockhead
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.
Stockhead's Break it Down brings you today's leading market news in under 90 seconds.
In this episode, host Sarah Hughan tells all on Paradigm Biopharmaceuticals' (ASX:PAR) support from the US Food and Drug Administration, paving the way for a pivotal clinical drug trial.
Looking for alternative and equally innovative avenues to address unmet needs, Paradigm identified the potential of pentosan polysulfate sodium.
Tune in to get the latest.
While Paradigm Pharmaceuticals is a Stockhead advertiser, it did not sponsor this content.
Originally published as Break it Down: Paradigm Biopharmaceuticals en route to Phase 3 clinical trial with FDA support
Closing Bell: Iron ore lifts ASX record
The ASX hit a record high on Thursday, driven by mining stocks, while the unemployment rate remained tight at 4.2%.
ASX recovers well from Fed hangover
The ASX reached a new record high this morning following the first rate cut from the US Fed in more than four years. It has since fallen back again, but the day is still young-ish yet…